Comments Regarding Quantitative Labeling of Sodium, Potassium, and Phosphorus for OTC and Prescription Drug Products Share page: Docket Number: FDA-2021-D-0528 Download Document Issues: OTC Medicines Other Issues Labeling Quality Related Posts Press Releases and Statements CHPA Response to Study Examining Prescription Acid Reflux Drugs Apr 25, 2024 Articles Polibrief: Consumer Data Privacy: State Efforts to Preserve Privacy Apr 16, 2024 Press Releases and Statements Self-Care Industry Representatives Participate in Capitol Hill Briefing Highlighting Legislative Priorities Apr 11, 2024